Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q2 FY21 results · Jul–Sep 2020
Ajanta Pharma reported revenue from operations of ₹715.91 crore (up 11.4% from Q2 FY20) and net profit of ₹170.22 crore (up 46.3% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 715.91 | 642.76 | +11.4% | 668.20 | +7.1% |
| Other income | 4.85 | 13.22 | −63.3% | 13.12 | −63.0% |
| Total income | 720.76 | 655.98 | +9.9% | 681.32 | +5.8% |
| Profit before tax | 249.24 | 161.56 | +54.3% | 206.69 | +20.6% |
| Net profit for the period | 170.22 | 116.36 | +46.3% | 147.76 | +15.2% |
| EPS, basic (₹) | 19.51 | 13.34 | +46.3% | 16.93 | +15.2% |
| Net margin (%) | 23.8 | 18.1 | 22.1 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 676.51 | 559.45 | +20.9% | 560.85 | +20.6% |
| Other income | 86.24 | 39.31 | +119.4% | 13.10 | +558.3% |
| Total income | 762.75 | 598.76 | +27.4% | 573.95 | +32.9% |
| Profit before tax | 308.53 | 160.83 | +91.8% | 158.47 | +94.7% |
| Net profit for the period | 225.22 | 120.70 | +86.6% | 115.69 | +94.7% |
| EPS, basic (₹) | 25.81 | 13.83 | +86.6% | 13.26 | +94.6% |
| Net margin (%) | 33.3 | 21.6 | 20.6 |
Consolidated
- Filed with BSE
- 04 Nov 2020, 17:23 IST
- Board meeting
- 03 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Nov 2020, 17:23 IST
- Board meeting
- 03 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE